Interview: Novartis's Big Hopes For Beovu

Drug Gets EU Okay For Wet AMD

 
• By Kevin Grogan

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.

Pensioner
AMD affects 1.7 million people in Europe. • Source: Shutterstock

More from Sensory

More from Therapy Areas